Meet the OBR Editorial Board

Editor's Note: At OBR we have created an editorial board of renown thought leaders in different cancer disease areas. The role of our editorial board is to provide valuable insights through editorial commentary accompanying our daily news. We call it virtual access. By providing our insights into the daily news, you will have access into how these thought leading oncologists interpret the oncology news and events we carry in OBR daily. We hope that our editorial boards's insights will bring great value to the oncology community.

View all Editorial Board Member Commentary

Browse Editors by Section

member-photo

Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center

Comments

Personalised ‘Liquid Biopsy’ Could Detect Return Of Breast Cancer Nearly Eleven Months Earlier Than Hospital Scans

quotesLiquid biopsies have been shown to be as good as tumor biopsies in analyzing gene mutations that can…quotes

member-photo

Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Wood Johnson Medical School
Rutgers-CINJ Associate Director, Clinical Research
Director Clinical Oncology Research, RWJ-B Health System

Comments

Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors

quotesCongratulations to Dr von Mehren and her colleagues on a highly positive study of Ripretinib in refr…quotes

member-photo

Ted Okon

Executive Director
Community Oncology Alliance

Comments

PBM Middlemen Continue to Dodge Responsibility for Patient Suffering and Rising Drug Prices

quotesPBMs are getting more brazen in how they delay and deny cancer patients their oral drugs. Anyone in …quotes

member-photo

William McGivney, PhD

National Health Policy Expert

Comments

AMA Says Prior Authorizations Increasing, Interfering With Care Continuity

quotesPayer Prior Authorization: Intrusion, Disruption and Patient Harm Is it any surprise that the freq…quotes

member-photo

Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine
Grover C. Bagby Chair of Prostate Cancer Research
OHSU Knight Cancer Institute Deputy Director, OHSU Knight Cancer Institute, School of Medicine
Chief Medical Officer, CEDAR, OHSU Knight Cancer Institute, School of Medicine

Comments

Risks for Patients with Pre-existing Conditions on Novel Prostate Cancer Therapies

quotesCardiovascular complications are increased in patients treated with modern hormonal agents when comp…quotes

member-photo

H. Jack West, MD

Associate Clinical Professor, Medical Oncology
Executive Director, Employer Services
City of Hope Comprehensive Cancer Center
Duarte, CA

Comments

Update On The Phase III NEPTUNE Trial Of Imfinzi Plus Tremelimumab In Stage IV Non-Small Cell Lung Cancer

quotesDisappointing but not surprising. Despite the recent press release about CheckMate 227 results show…quotes

member-photo

Winston Wong, PharmD

President, W-Squared Group

Comments

Dana-Farber Cancer Institute Analyzes Clinical Pathway Use to Reduce Unwarranted Variation

quotesThis piece is a great example of a pathway program in process. Clinical pathways are not meant to b…quotes

member-photo

Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology
Department of Medicine,Cedars-Sinai Medical Center
Associate Director for Academic Program Development
Samuel Oschin Comprehensive Cancer Institute
Professor of Medicine and Urology, Emeritus
David Geffen School of Medicine at UCLA

Comments

CT Scans Can Reduce Lung Cancer Deaths, Study Finds

quotesThis long awaited trial performed by the National Cancer Institute demonstrates the benefits of low …quotes

member-photo

Dean Gesme, MD

FACP FACPE FASCO
President, Minnesota Oncology

Comments

Senate Bill’s Drug Pricing Provision Raises Industry Alarms

quotesIncluding patient assistance funding provided by manufacturers directly to patients in ASP pricing w…quotes

member-photo

Jeff Patton, M.D.

CEO
Tennessee Oncology

Comments

First Opinion: Physicians Aren’t ‘Burning Out.’ They’re Suffering From Moral Injury

quotesI found this article both fascinating and enlightening. I had not thought of "burnout" in terms of …quotes

member-photo

Thomas Marsland, MD

Vice President
Integrated Community Oncology Network
Former Community Representative
ASCO Board of Directors

Comments

COA Statement on Proposed Radiation Oncology Alternative Payment Model

quotesCOA absolutely has it right on this proposal. Mandatory participation in these proposed payment mod…quotes

member-photo

William Harwin MD

Florida Cancer Specialists
President and Managing Partner

Comments

Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas

quotesLike the data…quotes

member-photo

Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics

Professor and Chair, Department of Radiation Oncology

Interim Director, Samuel Oschin Comprehensive Cancer Institute

Cedars-Sinai Medical Center

Comments

Researchers Assess the Accuracy of 68Ga-PSMA-11 PET in Localizing Prostate Cancer

quotesSome of the leaders in the US from UCLA and UCSF report on their Ga68 PSMA PET scan results in prost…quotes